drugset / Trial / NCT04729608
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Phase 3
Terminated
366 enrolled
Aravive, Inc.
European Network of Gynaecological Oncological Trial Groups (ENGOT) · collabGOG Foundation · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination with PAC in patients with platinum resistant recurrent ovarian cancer.
Timeline
- Start
- 2021-04-22
- Primary completion
- 2023-08-04
- Completion
- 2023-08-04
Outcome
Outcome not reported
Stopped: “There were no significant differences in median PFS between batiraxcept + paclitaxel or paclitaxel alone arms. There was no detriment to overall survival. No new safety signals were identified.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Batiraxcept | Protein / enzyme biologic | — | — |
| Background | Paclitaxel | Small molecule | — | — |
Indications
No indication recorded.